Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12360456rdf:typepubmed:Citationlld:pubmed
pubmed-article:12360456lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:12360456lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:12360456lifeskim:mentionsumls-concept:C0291772lld:lifeskim
pubmed-article:12360456lifeskim:mentionsumls-concept:C0360055lld:lifeskim
pubmed-article:12360456lifeskim:mentionsumls-concept:C2917412lld:lifeskim
pubmed-article:12360456pubmed:issue4lld:pubmed
pubmed-article:12360456pubmed:dateCreated2002-10-2lld:pubmed
pubmed-article:12360456pubmed:abstractTextThe 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood. We determined the effect of Alos on regional cerebral blood flow (rCBF) in the absence and presence of rectal or sigmoid stimulation to evaluate 2 hypothesized mechanisms of therapeutic action: peripheral antinociception and inhibition of emotional motor system (EMS) regions in the brain.lld:pubmed
pubmed-article:12360456pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:languageenglld:pubmed
pubmed-article:12360456pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12360456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12360456pubmed:statusMEDLINElld:pubmed
pubmed-article:12360456pubmed:monthOctlld:pubmed
pubmed-article:12360456pubmed:issn0016-5085lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:MayerEmeran...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:BermanSteven...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:ChangLinLlld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:SuyenobuBrand...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:DerbyshireStu...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:StainsJeanJlld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:FitzgeraldLea...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:MandelkernMar...lld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:HammLynnLlld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:VogtBrentBlld:pubmed
pubmed-article:12360456pubmed:authorpubmed-author:NaliboffBruce...lld:pubmed
pubmed-article:12360456pubmed:issnTypePrintlld:pubmed
pubmed-article:12360456pubmed:volume123lld:pubmed
pubmed-article:12360456pubmed:ownerNLMlld:pubmed
pubmed-article:12360456pubmed:authorsCompleteYlld:pubmed
pubmed-article:12360456pubmed:pagination969-77lld:pubmed
pubmed-article:12360456pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:meshHeadingpubmed-meshheading:12360456...lld:pubmed
pubmed-article:12360456pubmed:year2002lld:pubmed
pubmed-article:12360456pubmed:articleTitleCondition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.lld:pubmed
pubmed-article:12360456pubmed:affiliationCURE/Neuroenteric Disease Program, Department of Medicine, University of California School of Medicine, Los Angeles, California 90073, USA.lld:pubmed
pubmed-article:12360456pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12360456pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12360456pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12360456pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12360456pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12360456lld:pubmed